Latest Pharmaceutical Innovation News

Acrux Limited has received a $3.04 million R&D Tax Incentive rebate for FY25 and fully repaid its short-term funding facility, underscoring its commitment to Australian pharmaceutical innovation.

Mesoblast Limited is set to release its full-year financial results and operational highlights for 2025, spotlighting its FDA-approved cell therapy and expanding global partnerships.

Firebrick Pharma has raised $0.2 million in a placement well below its $1.6 million target, prompting a review of its expansion and product development plans for Nasodine.

Opyl Limited has taken a bold step into digital assets by acquiring approximately 2 Bitcoin and securing a $2 million finance facility backed by these holdings, signaling a strategic pivot towards blockchain integration in healthcare technology.

Opyl Limited unveils a bold strategic pivot to enhance its AI-driven drug discovery platform, leveraging a vast proprietary dataset and leadership upgrades to redefine clinical trial innovation.

Firebrick Pharma has unexpectedly withdrawn its planned share placement, raising questions about its capital strategy amid ongoing product launches.

Algorae Pharmaceuticals has secured a significant A$318,771 R&D tax incentive rebate from the Australian Taxation Office, providing a non-dilutive cash injection to advance its AI-driven drug discovery programs.

EVE Health Group has executed a binding agreement to acquire Australian biotech Nextract, targeting rapid-onset treatments in the $16 billion global erectile dysfunction and dysmenorrhea markets. The acquisition, supported by a $1.5 million capital raise and share consolidation, marks a strategic shift into regulated pharmaceutical channels.